BR112021026192A2 - Marcador de diagnóstico para câncer pancreático - Google Patents

Marcador de diagnóstico para câncer pancreático

Info

Publication number
BR112021026192A2
BR112021026192A2 BR112021026192A BR112021026192A BR112021026192A2 BR 112021026192 A2 BR112021026192 A2 BR 112021026192A2 BR 112021026192 A BR112021026192 A BR 112021026192A BR 112021026192 A BR112021026192 A BR 112021026192A BR 112021026192 A2 BR112021026192 A2 BR 112021026192A2
Authority
BR
Brazil
Prior art keywords
pancreatic cancer
compound
provides
body fluid
protease activity
Prior art date
Application number
BR112021026192A
Other languages
English (en)
Inventor
Adam Lesner
Natalia Gruba
Original Assignee
Urteste S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL430348A external-priority patent/PL241174B1/pl
Priority claimed from EP20150093.1A external-priority patent/EP3845664A1/en
Application filed by Urteste S A filed Critical Urteste S A
Publication of BR112021026192A2 publication Critical patent/BR112021026192A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Abstract

marcador de diagnóstico para câncer pancreático. a invenção fornece um composto da fórmula (1) x1-thr-thr-ala-arg-x2, sendo que a clivagem do composto em um fragmento 1 que compreende x1 e um fragmento 2 que compreende x2 gera um sinal detectável. a invenção fornece, ainda, um método in vitro para detectar a atividade de protease em fluido corporal de um sujeito que compreende colocar o fluido corporal em contato com o composto e detectar um sinal, em que o fluido corporal pode compreender uma enzima hidrolítica derivada de células cancerosas pancreáticas. ademais, a invenção fornece um kit que compreende o composto e um tampão de medida. ainda, a invenção fornece o uso do composto, o método in vitro ou o kit para a detecção de câncer pancreático ou para o monitoramento de um sujeito com suspeita de ou que tem um risco aumentado de desenvolver ou que teve câncer pancreático. a invenção também fornece o uso do composto em um método para tratar câncer pancreático, que compreende executar o método in vitro para detectar a atividade de protease em um fluido corporal e tratar o câncer pancreático em um sujeito no qual a atividade de protease foi detectada.
BR112021026192A 2019-06-24 2020-06-23 Marcador de diagnóstico para câncer pancreático BR112021026192A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PL430348A PL241174B1 (pl) 2019-06-24 2019-06-24 Związek chemiczny-marker diagnostyczny nowotworu trzustki oraz sposób diagnozowania in vitro nowotworu trzustki
EP20150093.1A EP3845664A1 (en) 2020-01-02 2020-01-02 Novel diagnostic marker for prostate cancer
EP20166354 2020-03-27
PCT/EP2020/067542 WO2020260309A1 (en) 2019-06-24 2020-06-23 Novel diagnostic marker for pancreatic cancer

Publications (1)

Publication Number Publication Date
BR112021026192A2 true BR112021026192A2 (pt) 2022-06-07

Family

ID=71103402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026192A BR112021026192A2 (pt) 2019-06-24 2020-06-23 Marcador de diagnóstico para câncer pancreático

Country Status (11)

Country Link
US (1) US20220251625A1 (pt)
EP (1) EP3987050A1 (pt)
JP (1) JP2022538862A (pt)
KR (1) KR20220024867A (pt)
CN (1) CN114096555A (pt)
AU (1) AU2020306623A1 (pt)
BR (1) BR112021026192A2 (pt)
CA (1) CA3144839A1 (pt)
IL (1) IL289348A (pt)
MX (1) MX2021016095A (pt)
WO (1) WO2020260309A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL440782A1 (pl) * 2022-03-29 2023-10-02 Urteste Spółka Akcyjna Związek - marker diagnostyczny raka jelita, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka jelita, zestaw zawierający taki związek oraz zastosowania takiego związku i sposób leczenia raka jelita
PL440976A1 (pl) * 2022-04-20 2023-10-23 Urteste Spółka Akcyjna Związek - marker diagnostyczny raka nerki, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka nerki, zestaw zawierający taki związek oraz zastosowania takiego związku i sposób leczenia raka nerki
PL441568A1 (pl) * 2022-06-28 2024-01-03 Urteste Spółka Akcyjna Związek - marker diagnostyczny raka trzonu macicy, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka trzonu macicy, zestaw zawierający taki związek oraz zastosowania takiego związku i sposób leczenia raka trzonu macicy
PL442379A1 (pl) * 2022-09-28 2024-04-02 Urteste Spółka Akcyjna Związek - marker diagnostyczny raka jajnika, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka jajnika, zestaw zawierający taki związek oraz zastosowania takiego związku i sposób leczenia raka jajnika

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038744A2 (en) * 2000-10-18 2002-05-16 Incyte Genomics, Inc. Proteases
FR2826656B1 (fr) * 2001-06-29 2003-09-12 Genethon Iii Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
EP2943585B1 (en) * 2013-01-09 2018-07-11 Friedrich-Alexander-Universität Erlangen-Nürnberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
WO2016135882A1 (ja) * 2015-02-25 2016-09-01 オリンパス株式会社 十二指腸液試料の膵液由来成分検出用試料としての適性評価方法
EP3423473A4 (en) * 2016-03-04 2019-10-30 New York University VIRUS VECTORS FOR EXPRESSING MULTIPLE EPITOPES OF TUMOR ASSOCIATED ANTIGENES TO INDUCT ANTITUMORIMMUNITY
JP2021507706A (ja) * 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ， インコーポレイテッド 放出セグメントおよびそれを含む結合組成物

Also Published As

Publication number Publication date
MX2021016095A (es) 2022-02-03
JP2022538862A (ja) 2022-09-06
IL289348A (en) 2022-02-01
AU2020306623A1 (en) 2022-01-27
CN114096555A (zh) 2022-02-25
KR20220024867A (ko) 2022-03-03
US20220251625A1 (en) 2022-08-11
EP3987050A1 (en) 2022-04-27
WO2020260309A1 (en) 2020-12-30
CA3144839A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
BR112021026192A2 (pt) Marcador de diagnóstico para câncer pancreático
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ591437A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104215632B (zh) 一种稳定的脂肪酶试剂盒
NZ592365A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112014013082A2 (pt) método para detectar adutos nucleossomos
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
BRPI0208597B8 (pt) meio de detecção de staphylococcus aureus e/ou estafilococos com coagulose positiva e método de identificação de bactéria (s) da espécie staphylococcus aureus em uma amostra
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR0112262A (pt) Diagnóstico precoce de doenças conformacionais
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
CO6741144A2 (es) Indicador vaginal para detectar biomarcadores de una buena salud
Nolano et al. Epidermal innervation morphometry by immunofluorescence and bright‐field microscopy
AR048031A1 (es) Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes
ATE533855T1 (de) Testverfahren zum nachweis lebensfähiger mikrobenzellen in einer probe
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
WO2009057294A1 (ja) 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法
WO2022056313A3 (en) Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
NZ598741A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample
Gao et al. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non–Small-Cell Lung Cancer
CN106537150B (zh) 胰脏疾病判定方法